Ramp vs Procurify for a Multi-Location MedSpa Group

Product ordered for injectable treatments typically has to be traceable by lot number for both regulatory and liability reasons, and an expired or improperly stored unit used on a patient is a real safety issue, not just a wasted purchase. A purchase order system that ties each order to a specific location and captures the vendor and lot information at the point of order gives you that traceability as a normal part of ordering, rather than as a separate inventory audit someone has to run periodically.

A card charge alone doesn't carry lot information, so if injectables are being bought on card without a parallel inventory system tracking lots, that gap has to be closed somewhere else before it becomes a safety or compliance problem.

Skincare retail product, front-desk supplies and routine consumables that aren't part of a clinical treatment don't carry the same tracking requirements, and a front desk that's out of retail product for a specific line shouldn't have to wait on a formal requisition to reorder it. A card with a spend limit and vendor restrictions, separate from however clinical product is ordered, covers this category well.

Keeping these two categories on separate purchasing tracks, clinical product through a tracked requisition process and retail supplies through a faster card-based process, avoids the two most common failure modes: slowing down retail reordering unnecessarily, or letting clinical product slip through without the lot tracking it actually needs.

Aesthetic devices, laser and body-contouring equipment especially, are typically leased or financed, and a decision to add or replace a device at one location affects that location's treatment menu and revenue potential directly. This is a capital decision that belongs above the location manager's authority, reviewed against the group's overall device fleet and each location's actual utilization, not decided location by location based on whichever rep made the best pitch that week.

A requisition system with an approval chain above the location level is the right structure for this, ensuring a new device commitment gets evaluated against what the group already has and what a location can realistically utilize before the lease is signed. Skipping that review tends to produce a fleet of devices that mirrors which location manager was most persuasive to a sales rep, rather than one that matches where patient demand actually supports the investment.

A multi-location group faces the same tension a lot of multi-site businesses do: central control is what makes negotiated vendor terms and consistent clinical standards possible, but too much central control on routine purchasing frustrates location managers who need to react to what their own patients and schedule actually need. The practical split is clinical product and capital equipment centralized, with clear lot tracking and approval chains, and routine retail and supply purchasing left fast and location-level.

Groups that centralize everything equally tend to see location managers quietly work around the system for routine purchases, which defeats the purpose without anyone having decided that was the tradeoff they wanted.

A practical split between clinical and routine purchasing looks like this:

• Order injectables and other expiration-dated clinical product through purchase orders tied to a location, capturing vendor and lot information at the point of order.
• Keep injectables off cards unless a parallel inventory system tracks lots, since a card charge alone carries no lot information.
• Put retail skincare and front-desk supplies on a card with a spend limit and vendor restrictions so the front desk can reorder without a formal requisition.
• Review device leases and replacements above the location manager, against the group's overall device fleet and each location's revenue potential.
• Roll up ordering across locations so patterns, such as small frequent batches that miss a volume discount threshold, become visible.

Say one location has been ordering a particular injectable line in smaller, more frequent batches than the group's other locations, at a slightly worse per-unit price because it's below the vendor's volume discount threshold each time. Without a system that rolls up ordering across locations, that pattern is invisible, it just looks like a location managing its own inventory reasonably. With purchase orders tied to a shared vendor structure, that ordering pattern becomes visible immediately, and the fix, batching that location's orders to hit the volume discount, is a straightforward correction once someone can actually see it happening. Multiply that gap across several product lines and several locations and it adds up to real money left on the table every quarter, none of it because anyone made a bad decision, just because nobody had the visibility to catch it.